CytomX Therapeutics (CTMX) Non-Current Deffered Revenue (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Non-Current Deffered Revenue data on file, last reported at $979000.0 in Q1 2026.

• Quarterly Non-Current Deffered Revenue fell 93.96% year-over-year to $979000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $979000.0 (down 93.96% YoY) and the FY2025 annual result came in at $1.6 million, down 94.08% from the prior year.
• Non-Current Deffered Revenue retreated to $979000.0 in Q1 2026, from $1.6 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $222.1 million in Q1 2022 to a low of $979000.0 in Q1 2026.
• A 5-year average of $85.7 million and a median of $59.7 million in 2024 frame the typical range for Non-Current Deffered Revenue.
• Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue dropped 17.06% — and 2025, when it tumbled 94.08%.
• Tracing CTMX's Non-Current Deffered Revenue over 5 years: stood at $180.1 million in 2022, then sank by 55.54% to $80.0 million in 2023, then sank by 66.44% to $26.9 million in 2024, then plunged by 94.08% to $1.6 million in 2025, then tumbled by 38.43% to $979000.0 in 2026.
• The last three Non-Current Deffered Revenue figures came in at $979000.0 (Q1 2026), $1.6 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.